The public health impact of recombinant herpes zoster vaccination in adults over 50 years in Spain

• প্রধান লেখক: Andrea García (Author), Laura Amanda Vallejo-Aparicio (Author), Rosario Cambronero Martinez (Author)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

The recombinant zoster vaccine (RZV) is included in the Spanish National Immunisation Programme for adults 65 years of age (years), with a potential progressive catch-up program for adults 66-80 years, starting with 80 years. However, the risk of herpes zoster (HZ) increases significantly from 50 ye...